drugset / Trial / NCT01406600

Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

NCT01406600

RandomizedParallel-groupOpen-labelTreatment

Summary

Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been investigated about its safety and efficacy comparing with urinary hCG, but still the optimal dose of rhCG is questionable. From former studies, there only have been proven that high dose of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety of 250mcg and 500mcg of rhCG in ART treatment cycle.

Timeline

Start
2011-09
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ovidrel Protein / enzyme biologic 250 ug
Subject Ovidrel Protein / enzyme biologic 500 ug

Indications

No indication recorded.